1
|
Zhang Z, Dauvilliers Y, Plazzi G, Mayer G, Lammers G, Santamaria J, Gaig C, Partinen M, Overeem S, Rio-Villegas RD, Šonka K, Peraita-Adrados R, Heinzer R, Wierzbicka A, Högl B, Manconi M, Feketeova E, da Silva A, Bušková J, Bassetti C, Barateau L, Pizza F, Gool J, Fronczek R, Khatami R. Idling for decades: a European study on risk factors associated with long time to narcolepsy diagnosis. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
2
|
Gool J, Zhang Z, Oei M, Mathias S, Dauvilliers Y, Mayer G, Plazzi G, del Rio-Villegas R, Santamaria J, Šonka K, Partinen M, Overeem S, Peraita-Adrados R, Heinzer R, Martins da Silva A, Högl B, Wierzbicka A, Heidbreder A, Feketeova E, Manconi M, Bušková J, Canellas F, Bassetti C, Barateau L, Pizza F, Schmidt M, Fronczek R, Khatami R, Lammers G. Unsupervised clustering of central hypersomnolence disorders enables data-driven phenotyping: toward more reliable diagnostic criteria. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
3
|
Bäßler FS, Zafar A, Mayer G, Schultz JH. Barriers to access cancer screening and treatment services in
Germany. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
4
|
Mayer G, Hummel S, Zafar A, Schultz JH. Konzepte der Personalisierung in der Behandlung psychischer
Erkrankungen: Ein Herangehensmodell für ein Scoping Review und erste
Ergebnisse. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
5
|
Mayer G, Shpilt Z, Kowalski H, Tshuva EY, Friedler A. Targeting Protein Interaction Hotspots Using Structured and Disordered Chimeric Peptide Inhibitors. ACS Chem Biol 2022; 17:1811-1823. [PMID: 35758642 DOI: 10.1021/acschembio.2c00177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The main challenge in inhibiting protein-protein interactions (PPI) for therapeutic purposes is designing molecules that bind specifically to the interaction hotspots. Adding to the complexity, such hotspots can be within both structured and disordered interaction interfaces. To address this, we present a strategy for inhibiting the structured and disordered hotspots of interactions using chimeric peptides that contain both structured and disordered parts. The chimeric peptides we developed are comprised of a cyclic structured part and a disordered part, which target both disordered and structured hotspots. We demonstrate our approach by developing peptide inhibitors for the interactions of the antiapoptotic iASPP protein. First, we developed a structured, α-helical stapled peptide inhibitor, derived from the N-terminal domain of MDM2. The peptide bound two hotspots on iASPP at the low micromolar range and had a cytotoxic effect on A2780 cancer cells with a half-maximal inhibitory concentration (IC50) value of 10 ± 1 μM. We then developed chimeric peptides comprising the structured stapled helical peptide and the disordered p53-derived LinkTer peptide that we previously showed to inhibit iASPP by targeting its disordered RT loop. The chimeric peptide targeted both structured and disordered domains in iASPP with higher affinity compared to the individual structured and disordered peptides and caused cancer cell death. Our strategy overcomes the inherent difficulty in inhibiting the interactions of proteins that possess structured and disordered regions. It does so by using chimeric peptides derived from different interaction partners that together target a much wider interface covering both the structured and disordered domains. This paves the way for developing such inhibitors for therapeutic purposes.
Collapse
Affiliation(s)
- Guy Mayer
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel
| | - Zohar Shpilt
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel
| | - Hadar Kowalski
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel
| | - Edit Y Tshuva
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel
| | - Assaf Friedler
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel
| |
Collapse
|
6
|
Affiliation(s)
- Johnny N. Naoum
- Institute of Chemistry, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
| | - Israel Alshanski
- Institute of Chemistry, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
- Center of Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
| | - Guy Mayer
- Institute of Chemistry, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
- Center of Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
| | - Poriah Strauss
- Institute of Chemistry, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
- Center of Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
| | - Mattan Hurevich
- Institute of Chemistry, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
- Center of Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Edmond Safra Campus, Givat Ram, Jerusalem 91904, Israel
| |
Collapse
|
7
|
Doppler K, Antelmi E, Kuzkina A, Donadio V, Incensi A, Plazzi G, Pizza F, Marelli S, Ferini-Strambi L, Tinazzi M, Mayer G, Sittig E, Booij J, Sedghi A, Oertel WH, Volkmann J, Sommer C, Janzen A, Liguori R. Consistent skin α-synuclein positivity in REM sleep behavior disorder - A two center two-to-four-year follow-up study. Parkinsonism Relat Disord 2021; 86:108-113. [PMID: 33895068 DOI: 10.1016/j.parkreldis.2021.04.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 03/08/2021] [Accepted: 04/12/2021] [Indexed: 11/19/2022]
Abstract
OBJECTIVE/METHODS Phosphorylated alpha-synuclein (p-syn) in dermal nerves of patients with isolated REM sleep behavior disorder (iRBD) is detectable by immunofluorescence-labeling. Skin-biopsy-p-syn-positivity was recently postulated to be a prodromal marker of Parkinson's disease (PD) or related synucleinopathies. Here, we provide two-to four-year clinical and skin biopsy follow-up data of 33 iRBD patients, whose skin biopsy findings at baseline were reported in 2017. RESULTS Follow-up biopsies were available from 25 patients (18 positive at baseline) and showed consistent findings over time in 24 patients. One patient converted from skin-biopsy-negativity to -positivity. P-syn-positivity was observed in iRBD patients who still had a normal FP-CIT-SPECT two years later. Clinically, five of the 23 at baseline skin-biopsy-positive patients (21.7%) had converted to PD or dementia with Lewy bodies at follow-up, but none of the skin-biopsy-negative patients. CONCLUSIONS Dermal p-syn in iRBD is most probably an early consistent marker of synucleinopathy and may support other indicators of conversion to manifest disease state.
Collapse
Affiliation(s)
- K Doppler
- University Hospital Würzburg, Department of Neurology, Würzburg, Germany.
| | - E Antelmi
- Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Italy
| | - A Kuzkina
- University Hospital Würzburg, Department of Neurology, Würzburg, Germany
| | - V Donadio
- IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - A Incensi
- IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - G Plazzi
- Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Italy; IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - F Pizza
- Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Italy; IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - S Marelli
- Vita-Salute San Raffaele University, Milan, Italy, IRCCS San Raffaele Scientific Institute, Department of Clinical Neurosciences, Neurology - Sleep Disorders Centre, Milan, Italy
| | - L Ferini-Strambi
- Vita-Salute San Raffaele University, Milan, Italy, IRCCS San Raffaele Scientific Institute, Department of Clinical Neurosciences, Neurology - Sleep Disorders Centre, Milan, Italy
| | - M Tinazzi
- Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - G Mayer
- Department of Neurology, Philipps University Marburg, Germany
| | - E Sittig
- Department of Neurology, Philipps University Marburg, Germany
| | - J Booij
- Department of Nuclear Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, the Netherlands
| | - A Sedghi
- University Hospital Würzburg, Department of Neurology, Würzburg, Germany; Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - W H Oertel
- Department of Neurology, Philipps University Marburg, Germany; Institute for Neurogenomics, Helmholtz Center for Health and Environment, München-Neuherberg, Germany
| | - J Volkmann
- University Hospital Würzburg, Department of Neurology, Würzburg, Germany
| | - C Sommer
- University Hospital Würzburg, Department of Neurology, Würzburg, Germany
| | - A Janzen
- Department of Neurology, Philipps University Marburg, Germany
| | - R Liguori
- Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Italy; IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy
| |
Collapse
|
8
|
Beer AGE, Laille E, Neuwirt H, Mayer G, Stauder R. Azacitidine is removed effectively by hemodialysis. Leuk Lymphoma 2020; 62:743-745. [PMID: 33100080 DOI: 10.1080/10428194.2020.1838505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- A G E Beer
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria
| | - E Laille
- Bristol Myers Squibb (formerly Celgene Corporation), Summit, NJ, USA
| | - H Neuwirt
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria
| | - G Mayer
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria
| | - R Stauder
- Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
9
|
Mayer G, Guba A. Role of the Nonrotating Decay Heat Removal Blower Pressure Loss in ALLEGRO Reactor. Journal of Nuclear Engineering and Radiation Science 2020. [DOI: 10.1115/1.4045805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Abstract
ALLEGRO is a helium-cooled fast reactor, which is being developed by the Czech Republic, France, Hungary, Slovakia, and Poland. It will be the demonstrator of the GFR-2400-MWth Generation IV gas-cooled fast reactors. In ALLEGRO, a three-loop safety system is designed to remove decay heat during accident conditions. The nonrotating blower blades may represent a huge pressure loss in the decay heat removal loop (DHR), which hinders natural circulation. The lower the pressure loss coefficient of the DHR blower blades is, the better cooling is available during natural circulation. On the other hand, a large core bypass develops if a DHR valve is opened inadvertently during normal operation. In this case, the higher DHR blower pressure loss is better from core cooling point of view. Consequently, the low pressure loss of the DHR blower is advantageous for core cooling in station blackout (SBO) event but disadvantageous for inadvertent DHR valve opening event. Both the above-mentioned cases may lead to insufficient core cooling in accident conditions, which threatens the integrity of the reactor core. In this study, we present CATHARE thermohydraulic calculations to assess the sensitivity of the DHR blower pressure loss coefficient for the above-mentioned two cases.
Collapse
Affiliation(s)
- G. Mayer
- Thermohydraulics Department, Hungarian Academy of Sciences Centre for Energy Research (MTA EK), P.O. Box 49, Budapest H-1525, Hungary
| | - A. Guba
- Thermohydraulics Department, Hungarian Academy of Sciences Centre for Energy Research (MTA EK), P.O. Box 49, Budapest H-1525, Hungary
| |
Collapse
|
10
|
Mayer G, Shpilt Z, Bressler S, Marcu O, Schueler‐Furman O, Tshuva EY, Friedler A. Front Cover: Targeting an Interaction Between Two Disordered Domains by Using a Designed Peptide (Chem. Eur. J. 45/2020). Chemistry 2020. [DOI: 10.1002/chem.202002213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Guy Mayer
- The Institute of Chemistry The Hebrew University of Jerusalem Edmond J. Safra Campus, Givat Ram Jerusalem Israel
| | - Zohar Shpilt
- The Institute of Chemistry The Hebrew University of Jerusalem Edmond J. Safra Campus, Givat Ram Jerusalem Israel
| | - Shachar Bressler
- The Institute of Chemistry The Hebrew University of Jerusalem Edmond J. Safra Campus, Givat Ram Jerusalem Israel
| | - Orly Marcu
- Department of Microbiology and Molecular Genetics Institute for Medical Research Israel-Canada Faculty of Medicine The Hebrew University of Jerusalem Jerusalem Israel
| | - Ora Schueler‐Furman
- Department of Microbiology and Molecular Genetics Institute for Medical Research Israel-Canada Faculty of Medicine The Hebrew University of Jerusalem Jerusalem Israel
| | - Edit Y. Tshuva
- The Institute of Chemistry The Hebrew University of Jerusalem Edmond J. Safra Campus, Givat Ram Jerusalem Israel
| | - Assaf Friedler
- The Institute of Chemistry The Hebrew University of Jerusalem Edmond J. Safra Campus, Givat Ram Jerusalem Israel
| |
Collapse
|
11
|
Mayer G, Shpilt Z, Bressler S, Marcu O, Schueler-Furman O, Tshuva EY, Friedler A. Targeting an Interaction Between Two Disordered Domains by Using a Designed Peptide. Chemistry 2020; 26:10240-10249. [PMID: 32181542 DOI: 10.1002/chem.202000465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 03/14/2020] [Indexed: 11/09/2022]
Abstract
Intrinsically disordered regions in proteins (IDRs) mediate many disease-related protein-protein interactions. However, the unfolded character and continuous conformational changes of IDRs make them difficult to target for therapeutic purposes. Here, we show that a designed peptide based on the disordered p53 linker domain can be used to target a partner IDR from the anti-apoptotic iASPP protein, promoting apoptosis of cancer cells. The p53 linker forms a hairpin-like structure with its two termini in close proximity. We designed a peptide derived from the disordered termini without the hairpin, designated as p53 LinkTer. The LinkTer peptide binds the disordered RT loop of iASPP with the same affinity as the parent p53 linker peptide, and inhibits the p53-iASPP interaction in vitro. The LinkTer peptide shows increased stability to proteolysis, penetrates cancer cells, causes nuclei shrinkage, and compromises the viability of cells. We conclude that a designed peptide comprising only the IDR from a peptide sequence can serve as an improved inhibitor since it binds its target protein without the need for pre-folding, paving the way for therapeutic targeting of IDRs.
Collapse
Affiliation(s)
- Guy Mayer
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Zohar Shpilt
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Shachar Bressler
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Orly Marcu
- Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Ora Schueler-Furman
- Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Edit Y Tshuva
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Assaf Friedler
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| |
Collapse
|
12
|
Mayer G, Shpilt Z, Bressler S, Marcu O, Schueler-Furman O, Tshuva EY, Friedler A. Targeting an Interaction Between Two Disordered Domains by Using a Designed Peptide. Chemistry 2020; 26:10156. [PMID: 32686878 DOI: 10.1002/chem.202002216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Invited for the cover of this issue is the group of Assaf Friedler at the Hebrew University of Jerusalem. The image depicts the protein-protein interactions reported in this work. Read the full text of the article at 10.1002/chem.202000465.
Collapse
Affiliation(s)
- Guy Mayer
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Zohar Shpilt
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Shachar Bressler
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Orly Marcu
- Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel
| | - Ora Schueler-Furman
- Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel
| | - Edit Y Tshuva
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| | - Assaf Friedler
- The Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
| |
Collapse
|
13
|
Samarasimhareddy M, Mayer G, Hurevich M, Friedler A. Multiphosphorylated peptides: importance, synthetic strategies, and applications for studying biological mechanisms. Org Biomol Chem 2020; 18:3405-3422. [DOI: 10.1039/d0ob00499e] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Advances in the synthesis of multiphosphorylated peptides and peptide libraries: tools for studying the effects of phosphorylation patterns on protein function and regulation.
Collapse
Affiliation(s)
- Mamidi Samarasimhareddy
- The Institute of Chemistry
- Edmond J. Safra Campus
- Givat Ram
- The Hebrew University of Jerusalem
- Jerusalem
| | - Guy Mayer
- The Institute of Chemistry
- Edmond J. Safra Campus
- Givat Ram
- The Hebrew University of Jerusalem
- Jerusalem
| | - Mattan Hurevich
- The Institute of Chemistry
- Edmond J. Safra Campus
- Givat Ram
- The Hebrew University of Jerusalem
- Jerusalem
| | - Assaf Friedler
- The Institute of Chemistry
- Edmond J. Safra Campus
- Givat Ram
- The Hebrew University of Jerusalem
- Jerusalem
| |
Collapse
|
14
|
Malhotra A, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo P, Mayer G, Sarniento K, Baladi M, Bron M, Chandler P, Lee L, Weaver T. Long-term effects of solriamfetol on quality of life in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnoea. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.674] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Donadio V, Doppler K, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, Sommer C, Liguori R, Oertel WH. Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. Eur J Neurol 2019; 26:1245-1251. [PMID: 30770596 DOI: 10.1111/ene.13939] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 02/07/2019] [Indexed: 01/15/2023]
Abstract
BACKGROUND AND PURPOSE Visualization of phosphorylated α-synuclein at serine 129 (p-syn) in skin nerves is a promising test for the in vivo diagnosis of synucleinopathies. Here the aim was to establish the intra- and inter-laboratory reproducibility of measurement of intraneural p-syn immunoreactivity in two laboratories with major expertise (Würzburg and Bologna). METHODS In total, 43 patients affected by Parkinson's disease (PD 21 patients), dementia with Lewy bodies (DLB 1), rapid eye movement sleep behaviour disorder (RBD 11), multiple system atrophy (MSA-P 4) and small fibre neuropathy (SFN 6) were enrolled. Skin biopsy was performed at the C7 paravertebral spine region and distal skin sites (thigh or leg). The analysis was standardized in both laboratories and carried out blinded on a single skin section double stained with antibodies to p-syn and the pan-axonal marker protein gene product 9.5. Fifty skin sections were randomly selected for the analysis: 25 from C7 and 25 from distal sites. Differently classified sections were re-evaluated to understand the reasons for the discrepancy. RESULTS The intra-laboratory analysis showed an excellent reproducibility both in Würzburg (concordance of classification 100% of sections; K = 1; P < 0.001) and Bologna (96% of sections; K = 0.92; P < 0.001). Inter-laboratory analysis showed reproducibility in 45 sections (90%; K = 0.8; P < 0.001) and a different classification in five sections, which was mainly due to fragmented skin samples or weak fluorescent signals. CONCLUSIONS Analysis of p-syn showed excellent inter- and intra-laboratory reproducibility supporting the reliability of this technique. The few ascertained discordances were important to further improve the standardization of this technique.
Collapse
Affiliation(s)
- V Donadio
- IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - K Doppler
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - A Incensi
- IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - A Kuzkina
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - A Janzen
- Philipps University, Marburg, Germany
| | - G Mayer
- Philipps University, Marburg, Germany
| | - J Volkmann
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - G Rizzo
- IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - E Antelmi
- IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - G Plazzi
- IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - C Sommer
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - R Liguori
- IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | | |
Collapse
|
16
|
Chahine LM, Iranzo A, Fernández-Arcos A, Simuni T, Seedorff N, Caspell-Garcia C, Amara AW, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, Oertel W. Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. NPJ Parkinsons Dis 2019; 5:2. [PMID: 30701189 PMCID: PMC6351563 DOI: 10.1038/s41531-018-0073-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 12/03/2018] [Indexed: 12/02/2022]
Abstract
REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson’s Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included. Assessments at the screening visit including DAT SPECT imaging, physical examination, cognitive function screen, and questionnaire-based non-motor assessment. The group with DAT binding deficit (n = 49) was compared to those without (n = 26). There were no significant differences in demographic or clinical features between the two groups. When recruiting RBD cohorts enriched for high risk of neurodegenerative disorders, our data support the need for objective biomarker assessments. The clinical characteristics of patients with rapid eye movement sleep behavior disorder (RBD) are not associated with reduced dopamine transporter binding, an established imaging biomarker of Parkinson’s Disease (PD). Because around 80 percent of patients with RBD develop PD, there is great hope that research on these patients will help uncover early signs of the disease and guide the development of neuroprotective therapies. Lana Chahine at The University of Pittsburgh, USA, and colleagues in the Parkinson Progression Markers Initiative (PPMI) Sleep Working Group analyzed the clinical features of 75 individuals with RBD. They found no significant differences in demographic features or in motor and non-motor symptoms between RBD patients with dopamine transporter binding deficit and those without. These findings highlight the need to assess dopamine transporter binding to determine the future risk of PD.
Collapse
Affiliation(s)
- L M Chahine
- 1Department of Neurology, The University of Pittsburgh, Pittsburgh, PA USA
| | - A Iranzo
- Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain
| | - A Fernández-Arcos
- Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain
| | - T Simuni
- 3Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL USA
| | - N Seedorff
- 4Department of Biostatistics, The University of Iowa, Iowa City, IA USA
| | - C Caspell-Garcia
- 4Department of Biostatistics, The University of Iowa, Iowa City, IA USA
| | - A W Amara
- 5Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL USA
| | - C Comella
- 6Department of Neurology, Rush University, Chicago, IL USA
| | - B Högl
- 7Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - J Hamilton
- 8The Michael J. Fox Foundation for Parkinson's Research, New York, NY USA
| | - K Marek
- 9Institute for Neurodegenerative Disorders, New Haven, CT USA
| | - G Mayer
- Department of Neurology, Hephata-Klinik, Hephata Hessisches Diakoniezentrum, e.V, Weibersbrunn, Germany
| | - B Mollenhauer
- 11Department of Neurology, University Medical Center, Göttingen, Germany.,12Paracelsus-Elena-Klinik, Kassel, Germany
| | - R Postuma
- 13Division of Neurology, McGill University, Montreal, QC Canada
| | - E Tolosa
- Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain
| | - C Trenkwalder
- 11Department of Neurology, University Medical Center, Göttingen, Germany.,12Paracelsus-Elena-Klinik, Kassel, Germany
| | - A Videnovic
- 14Department of Neurology, Massachusetts General Hospital, Boston, MA USA
| | - W Oertel
- 15Department of Neurology, Philipps University, Marburg, Germany.,16Charitable Hertie Foundation, Frankfurt/Main, Germany
| | | |
Collapse
|
17
|
Iosub-Amir A, Bai F, Sohn YS, Song L, Tamir S, Marjault HB, Mayer G, Karmi O, Jennings PA, Mittler R, Onuchic JN, Friedler A, Nechushtai R. The anti-apoptotic proteins NAF-1 and iASPP interact to drive apoptosis in cancer cells. Chem Sci 2018; 10:665-673. [PMID: 30774867 PMCID: PMC6349067 DOI: 10.1039/c8sc03390k] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Accepted: 11/19/2018] [Indexed: 01/01/2023] Open
Abstract
We reveal a novel interaction between the two anti-apoptotic proteins iASPP and NAF-1, which are overexpressed in many types of cancer cells, and propose that this interaction is required for apoptosis activation in cancer cells. A peptide derived from the interaction interface inhibits apoptosis in cells.
Suppression of apoptosis is a key Hallmark of cancer cells, and reactivation of apoptosis is a major avenue for cancer therapy. We reveal an interaction between the two anti-apoptotic proteins iASPP and NAF-1, which are overexpressed in many types of cancer cells and tumors. iASPP is an inhibitory member of the ASPP protein family, whereas NAF-1 belongs to the NEET 2Fe–2S protein family. We show that the two proteins are stimulated to interact in cells during apoptosis. Using peptide array screening and computational methods we mapped the interaction interfaces of both proteins to residues 764–778 of iASPP that bind to a surface groove of NAF-1. A peptide corresponding to the iASPP 764–780 sequence stabilized the NAF-1 cluster, inhibited NAF-1 interaction with iASPP, and inhibited staurosporine-induced apoptosis activation in human breast cancer, as well as in PC-3 prostate cancer cells in which p53 is inactive. The iASPP 764–780 IC50 value for inhibition of cell death in breast cancer cells was 13 ± 1 μM. The level of cell death inhibition by iASPP 764–780 was altered in breast cancer cells expressing different levels and/or variants of NAF-1, indicating that the peptide activity is associated with NAF-1 function. We propose that the interaction between iASPP and NAF-1 is required for apoptosis activation in cancer cells. This interaction uncovers a new layer in the highly complex regulation of cell death in cancer cells and opens new avenues of exploration into the development of novel anticancer drugs that reactivate apoptosis in malignant tumors.
Collapse
Affiliation(s)
- Anat Iosub-Amir
- Institute of Chemistry , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Fang Bai
- Center for Theoretical Biological Physics , Department of Physics , Rice University , Houston , TX 77005 , USA .
| | - Yang-Sung Sohn
- The Alexander Silberman Institute of Life Science , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Luhua Song
- Department of Biological Sciences , University of North Texas , Denton , TX 76203 , USA
| | - Sagi Tamir
- The Alexander Silberman Institute of Life Science , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Henri-Baptiste Marjault
- The Alexander Silberman Institute of Life Science , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Guy Mayer
- Institute of Chemistry , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Ola Karmi
- The Alexander Silberman Institute of Life Science , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Patricia A Jennings
- Department of Chemistry & Biochemistry , University of California at San Diego , La Jolla , CA 92093 , USA
| | - Ron Mittler
- Department of Surgery , University of Missouri School of Medicine , Christopher S. Bond Life Sciences Center , University of Missouri , 1201 Rollins St , Columbia , MO 65201 , USA
| | - José N Onuchic
- Center for Theoretical Biological Physics , Department of Physics , Rice University , Houston , TX 77005 , USA .
| | - Assaf Friedler
- Institute of Chemistry , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| | - Rachel Nechushtai
- The Alexander Silberman Institute of Life Science , The Hebrew University of Jerusalem , Edmond J. Safra Campus at Givat Ram , Jerusalem 91904 , Israel .
| |
Collapse
|
18
|
Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, De Cuypere G, Feldman J, Fraser L, Green J, Knudson G, Meyer WJ, Monstrey S, Adler RK, Brown GR, Devor AH, Ehrbar R, Ettner R, Eyler E, Garofalo R, Karasic DH, Lev AI, Mayer G, Meyer-Bahlburg H, Hall BP, Pfäfflin F, Rachlin K, Robinson B, Schechter LS, Tangpricha V, van Trotsenburg M, Vitale A, Winter S, Whittle S, Wylie KR, Zucker K. Normas de Atención para la salud de personas trans y con variabilidad de género. INT J TRANSGENDERISM 2018. [DOI: 10.1080/15532739.2018.1503902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
19
|
Mayer G, Mayer S, Waitz R. The Inhibitory Action of Adsorbed Undiluted Plasma (normal or pathological) on the Thromboplastin Generation Test. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1654517] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryIn considering errors made during the search for a weak inhibitor of thromboplastin generation in a patient suffering from multiple myeloma, the authors recall the inhibitory action of adsorbed undiluted plasma added to a thromboplastin generation test. They stress the non-specificity of this inhibitory action which is common to all adsorbed plasma (normal, myelomatous or hemophilic) added undiluted to the test of Biggs and Douglas.
Collapse
|
20
|
Mayer G, Mayer S, Waitz R. The „Bridge Effect”. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1654518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe “Bridge effect“ consists in the fact that an incomplete thromboplastin, tested by the thromboplastin generation test of Biggs and Douglas on a substrate having a deficiency in its own thromboplastin generation, coagulates it more slowly than a normal substrate. It is observed when the factorial deficiencies of the substrate and the thromboplastin correspond with each other (hemophilic — hemophilic, Christmas — Christmas), it is weak and inconstant (Christmas thromboplastin — hemophilic substrate) or non existent (hemophilic thromboplastin — Christmas substrate) when they are crossed. It is eliminated by an adequate correction of the substrate (AHG added to the hemophilic substrate, PTC added to the Christmas substrate). The “Bridge effect“ is a source of error which must be taken into account in the manipulation of thromboplastin generation tests.
Collapse
|
21
|
Domenyuk V, Liu X, Magee D, Gatalica Z, Stark A, Kennedy P, Rosenow M, Barker A, Berry D, Poste G, Halbert D, Hart C, Famulok M, Mayer G, Korn M, Miglarese M, Spetzler D. Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Malhotra A, Shapiro C, Pepin J, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo P, Mayer G, Sarmiento K, Baladi M, Li J, Chandler P, Lee L, Schwab R. 0620 A Long-Term Safety and Maintenance of Efficacy Study of Solriamfetol (JZP-110) in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apnea. Sleep 2018. [DOI: 10.1093/sleep/zsy061.619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Malhotra
- Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, CA
| | - C Shapiro
- University of Toronto, Toronto, ON, CANADA
| | - J Pepin
- Grenoble Alpes University Hospital, La Tronche, FRANCE
| | - J Hedner
- Sahlgrenska University Hospital, Gothenburg University, Gothenburg, SWEDEN
| | - M Ahmed
- Cleveland Sleep Research Center, Middleburg Heights, OH
| | | | - P Strollo
- University of Pittsburgh/Veterans Administration Pittsburgh Health System, Pittsburgh, PA
| | - G Mayer
- Hephata Klinik Schwalmstadt, Schimmelpfengstraße 6, GERMANY
- Philipps University, Marburg, GERMANY
| | - K Sarmiento
- San Francisco Veterans Administration Healthcare System, San Francisco, CA
| | - M Baladi
- Jazz Pharmaceuticals, Palo Alto, CA
| | - J Li
- Jazz Pharmaceuticals, Palo Alto, CA
| | | | - L Lee
- Jazz Pharmaceuticals, Palo Alto, CA
| | - R Schwab
- University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
23
|
Dauvilliers Y, Shapiro C, Mayer G, Lammers G, Emsellem H, Plazzi G, Chen D, Li J, Carter LP, Lee L, Black J, Thorpy MJ. 0619 Solriamfetol (JZP-110) for Treatment of Excessive Sleepiness in Narcoleptic Patients With and Without Cataplexy: Results From a Randomized, Phase 3, Clinical Trial. Sleep 2018. [DOI: 10.1093/sleep/zsy061.618] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Dauvilliers
- Reference National Center for Narcolepsy, Gui-de-Chauliac Hospital, CHU Montpelier, INSERM U1061, FRANCE
| | - C Shapiro
- University of Toronto, Toronto, ON, CANADA
| | - G Mayer
- Hephata Klinik, Schimmelpfengstraße, GERMANY
- Philipps University, Marburg, GERMANY
| | - G Lammers
- Department of Neurology, Leiden University Medical Centre, Leiden, NETHERLANDS
- Sleep-Wake Centre of the Stichting Epilepsie Instellingen Netherland, Heemstede, NETHERLANDS
| | - H Emsellem
- The Center for Sleep & Wake Disorders, Chevy Chase, MD
- George Washington University Medical Center, Washington, DC
| | - G Plazzi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITALY
| | - D Chen
- Jazz Pharmaceuticals, Palo Alto, CA
| | - J Li
- Jazz Pharmaceuticals, Palo Alto, CA
| | - L P Carter
- Jazz Pharmaceuticals, Palo Alto, CA
- University of Arkansas for Medical Sciences, Little Rock, AR
| | - L Lee
- Jazz Pharmaceuticals, Palo Alto, CA
| | - J Black
- Jazz Pharmaceuticals, Palo Alto, CA
- Stanford Center for Sleep Sciences and Medicine, Palo Alto, CA
| | | |
Collapse
|
24
|
Emsellem H, Thorpy MJ, Lammers G, Shapiro C, Mayer G, Plazzi G, Chen D, Li J, Carter LP, Ryan R, Black J, Dauvilliers Y. 0621 Measures of Function, Work Productivity, and Quality of Life From a Phase 3 Study of Solriamfetol (JZP-110) in Patients with Narcolepsy. Sleep 2018. [DOI: 10.1093/sleep/zsy061.620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Emsellem
- The Center for Sleep & Wake Disorders, Chevy Chase, MD
- George Washington University Medical Center, Washington, DC
| | | | - G Lammers
- Department of Neurology, Leiden University Medical Centre, Leiden, NETHERLANDS
| | - C Shapiro
- University of Toronto, Toronto, ON, CANADA
| | - G Mayer
- Hephata Klinik Schwalmstadt, Schimmelpfengstraße, GERMANY
- Philipps University, Marburg, GERMANY
| | - G Plazzi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITALY
| | - D Chen
- Jazz Pharmaceuticals, Palo Alto, CA
| | - J Li
- Jazz Pharmaceuticals, Palo Alto, CA
| | - L P Carter
- Jazz Pharmaceuticals, Palo Alto, CA
- University of Arkansas for Medical Sciences, Little Rock, AR
| | - R Ryan
- Jazz Pharmaceuticals, Palo Alto, CA
| | - J Black
- Jazz Pharmaceuticals, Palo Alto, CA
- Stanford Center for Sleep Sciences and Medicine, Palo Alto, CA
| | - Y Dauvilliers
- Reference National Center for Narcolepsy, Gui-de-Chauliac Hospital, CHU Montpelier, INSERM U1061, FRANCE
| |
Collapse
|
25
|
Guttowski D, Mayer G, Oertel WH, Kesper K, Rosenberg T. Validation of semiautomatic scoring of REM sleep without atonia in patients with RBD. Sleep Med 2018; 46:107-113. [PMID: 29773203 DOI: 10.1016/j.sleep.2018.03.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 02/20/2018] [Accepted: 03/13/2018] [Indexed: 11/29/2022]
Abstract
OBJECTIVE/BACKGROUND To evaluate REM sleep without atonia (RSWA) in REM sleep behavior disorder (RBD) several automatic algorithms have been developed. We aimed to validate our algorithm (Mayer et al., 2008) in order to assess the following: (1). capability of the algorithm to differentiate between RBD, night terror (NT), somnambulism (SW), Restless legs syndrome (RLS), and obstructive sleep apnea (OSA), (2). the cut-off values for short (SMI) and long muscle activity (LMI), (3). which muscles qualify best for differential diagnosis, and (4). the comparability of RSWA and registered movements between automatic and visual analysis of videometry. PATIENTS/METHODS RSWA was automatically scored according to Mayer et al., 2008 in polysomnographies of 20 RBD, 10 SW/NT, 10 RLS and 10 OSA patients. Receiver operating characteristic (ROC) curves were used to determine the sensitivity and specificity of SMI and LMI. Independent samples were calculated with t-tests. Boxplots were used for group comparison. The comparison between motor events by manual scoring and automatic analysis were performed with "Visual Basic for Applications" (VBA) for every hundredth second. RESULTS Our method discriminates RBD from SW/NT, OSA and RLS with a sensitivity of 72.5% and a specificity of 86.7%. Automatic scoring identifies more movements than visual video scoring. Mentalis muscle discriminates the sleep disorders best, followed by FDS, which was only recorded in SW/NT. Cut-off values for RSWA are comparable to those found by other groups. CONCLUSION The semi-automatic RSWA scoring method is capable to confirm RBD and to discriminate it with moderate sensitivity from other sleep disorders.
Collapse
Affiliation(s)
- D Guttowski
- Department of Trauma, Hand and Reconstructive Surgery, University Hospital Hamburg Eppendorf, UKE, Martinistr. 52, 20246 Hamburg, Germany
| | - G Mayer
- Hephata Klinik 34613 Schwalmstadt Schimmelpfengstr. 6 Germany; Philipps University Marburg, Department of Neurology, Baldinger Str. 35043 Marburg, Germany.
| | - W H Oertel
- Philipps University Marburg, Department of Neurology, Baldinger Str. 35043 Marburg, Germany
| | - K Kesper
- Philipps Universität Marburg, Sleep Laboratory, Dept. of Pneumology, Baldinger Str. 35043 Marburg, Germany
| | - T Rosenberg
- Bosse Klinik, Department of Neurology/Psychiatry, Hans-Lufft-Str. 5, 06886 Lutherstadt Wittenberg, Germany
| |
Collapse
|
26
|
Abstract
Standard dialysis with cuprophane membranes is known to stimulate the immune system. As a result of activation of macrophages various interleukins and tumor necrosis factor (TNF) are secreted, presenting further evidence of the poor biocompatibility of cuprophane. We investigated the immunogenic properties of three modern high-flux membranes. Seven patients were studied during hemodiafiltration sessions using either a polysulfone (F60, Fresenius), a polymethylmetacrylate (BK 2.1, Toray) or a cellulose triacetate (FB-210 U, Nipro) dialyzer in a hemodiafiltration procedure. Serial measurements were made during each treatment of interleukin-1β (II-1β), TNF, soluble IL-2 receptor (sII-2r), soluble CD4 (sCD4), soluble CD8 (sCD8), interferon gamma (IFNg) and neopterin. In contrast to the known increase of IL-1β, IL-2r and TNF with cuprophane membranes, none of the modern high-flux dialyzers stimulated the production of these factors. Significant decreases of neopterin and sCD4 were observed. IFNg and sCD8 did not change significantly. Our results suggest that the modern high-flux dialyzers are non-immunogenic, and thus provide further evidence of the superior biocompatibility of synthetic or semisynthetic membranes over the conventional cuprophane.
Collapse
Affiliation(s)
- D. Putz
- 2nd Department of Medicine, University of Vienna, Vienna - Austria
| | - U. Barnas
- 2nd Department of Medicine, University of Vienna, Vienna - Austria
| | - A. Luger
- 2nd Department of Medicine, University of Vienna, Vienna - Austria
| | - G. Mayer
- 2nd Department of Medicine, University of Vienna, Vienna - Austria
| | - W. Woloszczuk
- 2nd Department of Medicine, University of Vienna, Vienna - Austria
| | - H. Graf
- 2nd Department of Medicine, University of Vienna, Vienna - Austria
| |
Collapse
|
27
|
Gross V, Bährle R, Mayer G. Detection of cell proliferation in adults of the water bear Hypsibius dujardini (Tardigrada) via incorporation of a thymidine analog. Tissue Cell 2018; 51:77-83. [PMID: 29622091 DOI: 10.1016/j.tice.2018.03.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 02/12/2018] [Accepted: 03/10/2018] [Indexed: 12/15/2022]
Abstract
The taxon Tardigrada, commonly called "water bears", consists of microscopic, eight-legged invertebrates that are well known for their ability to tolerate extreme environmental conditions. Their miniscule body size means that tardigrades possess a small total number of cells, the number and arrangement of which may be highly conserved in some organs. Although mitoses have been observed in several organs, the rate and pattern of cell divisions in adult tardigrades has never been characterized. In this study, we incubated live tardigrades over a period of several days with a thymidine analog in order to visualize all cells that had divided during this time. We focus on the midgut, the largest part of the digestive system. Our results show that new cells in the midgut arise from the anterior and posterior ends of this organ and either migrate or divide toward its middle. These cells divide at a constant rate and all cells of the midgut epithelium are replaced in approximately one week. On the other hand, we found no cell divisions in the nervous system or any other major organs, suggesting that the cell turnover of these organs may be extremely slow or dependent on changing environmental conditions.
Collapse
Affiliation(s)
- V Gross
- Department of Zoology, Institute of Biology, University of Kassel, Heinrich-Plett-Straße 40, D-34132 Kassel, Germany.
| | - R Bährle
- Department of Zoology, Institute of Biology, University of Kassel, Heinrich-Plett-Straße 40, D-34132 Kassel, Germany
| | - G Mayer
- Department of Zoology, Institute of Biology, University of Kassel, Heinrich-Plett-Straße 40, D-34132 Kassel, Germany
| |
Collapse
|
28
|
Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang R, Xiao N, Greil R, Rinnerthaler G, Gampenrieder S, Heimberger AB, Berry DJ, Barker A, Demetri GD, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Miglarese MR, Famulok M, Mayer G, Spetzler D. Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Deconvolution of multi-nodal perturbations in cancer network architecture demands highly multiplexed profiling assays. We demonstrate the value of polyligand profiling of tumor systems states using libraries of single stranded oligodeoxynucleotides (ssODN) to distinguish between tumor tissue from breast cancer patients who did or did not derive benefit from treatment regimens containing trastuzumab.
Methods: This study included cases from women with invasive breast cancer who received chemotherapy+ trastuzumab (C+T) or trastuzumab monotherapy with available retrospective data on the time to next treatment (TTNT). A library of 2x1012 unique ssODN was exposed to FFPE tissues from patients who benefited (B) or not (NB) from trastuzumab-based regimens in several rounds of positive and negative selection. Two enriched libraries were screened on independent set of 42 B and 19 NB cases using a modified IHC protocol for detection of bound ssODNs. Poly-Ligand Profiles (PLP) were scored by a blinded pathologist. Two libraries, EL-NB and EL-B, showed significant p-values between groups of responders and non-responders. A Cox-PH model was fitted using either tumors' HER2 status or PLP test results as the independent variable. Median survival time was calculated from the Kaplan-Meier estimate. A separate group of 63 cases with TTNT data from chemotherapy without trastuzumab was used as a control to distinguish prognostic from predictive performance.
Results: The PLP scores of EL-NB and EL-B were assessed by receiver operating characteristic (ROC) curves and resulted in a combined AUC value of 0.81. EL-NB and EL-B were able to effectively classify B and NB patients with either HER2-negative/equivocal (AUC = 0.73) or HER2-positive cancers (AUC = 0.84). In contrast, HER2 status alone yielded an AUC value of 0.47. The combined PLP scores for the independent set of 63 patients treated with C excluding trastuzumab resulted in an AUC value of 0.53, indicating that the assay was predictive and not simply prognostic. Kaplan-Meier curves analysis shows that PLP+ cases have 429 days median TTNT, while PLP- cases have 129 days (HR = 0.38, log-rank p = 0.001). Analysis based on HER2 status showed no significant difference in TTNT between patients that were HER2+ (280 days) or HER2-negative/equivocal (336 days, HR = 1.27, log-rank p =0.45).
Summary: Performance of the PLP assay in differentiating patients who did or did not benefit from trastuzumab therapy outperforms the standard IHC assay for HER2 status. These results represent a promising step towards the development of a CDx to identify the 50-70% of HER2+ patients who will not benefit from trastuzumab. In addition, PLP also has the potential to identify the HER2-negative/equivocal patients who may benefit from trastuzumab-containing regimens.
Citation Format: Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang R, Xiao N, Greil R, Rinnerthaler G, Gampenrieder S, Heimberger AB, Berry DJ, Barker A, Demetri GD, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Miglarese MR, Famulok M, Mayer G, Spetzler D. Polyligand profiling differentiates cancer patients according to their benefit of treatment [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-09.
Collapse
Affiliation(s)
- V Domenyuk
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - Z Gatalica
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - R Santhanam
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - X Wei
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - A Stark
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - P Kennedy
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - B Toussaint
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - S Levenberg
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - R Wang
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - N Xiao
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - R Greil
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - G Rinnerthaler
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - S Gampenrieder
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - AB Heimberger
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - DJ Berry
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - A Barker
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - GD Demetri
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - J Quackenbush
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - JL Marshall
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - G Poste
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - JL Vacirca
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - GA Vidal
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - LS Schwartzberg
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - DD Halbert
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - A Voss
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - MR Miglarese
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - M Famulok
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - G Mayer
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - D Spetzler
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| |
Collapse
|
29
|
Pircher C, Schneeberger S, Boesmueller C, Agaimy A, Zoller H, Bale R, Henninger B, Mayer G, Neuwirt H. A rare case of Epstein-Barr virus-associated hepatosplenic smooth muscle tumors after kidney transplantation. Transpl Infect Dis 2018; 20:e12860. [PMID: 29427352 DOI: 10.1111/tid.12860] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 10/04/2017] [Accepted: 11/20/2017] [Indexed: 12/28/2022]
Abstract
A 27-year old caucasian male was diagnosed 2.7 years after kidney transplantation with Epstein-Barr virus (EBV)-associated smooth muscle tumors in liver and spleen. The reduction in immunosuppression and conversion from tacrolimus to sirolimus did not lead to a regression of the tumors. Additionally, the patient developed a cellular rejection of his renal allograft, which was successfully treated. A combined approach with stereotactic radiofrequency ablation (SRFA) and surgical resection was effective in the treatment of the tumors.
Collapse
Affiliation(s)
- C Pircher
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria
| | - S Schneeberger
- Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria
| | - C Boesmueller
- Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria
| | - A Agaimy
- Institute of Pathology, Friedrich-Alexander University of Erlangen-Nuremberg, University Hospital of Erlangen, Erlangen, Germany
| | - H Zoller
- Department of Internal Medicine I, Gastroenterology, Hepatology and Endocrinology, Medical University of Innsbruck, Innsbruck, Austria
| | - R Bale
- Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
| | - B Henninger
- Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
| | - G Mayer
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria
| | - H Neuwirt
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
30
|
Lenninger M, Schweibert N, Leierer J, Weigel G, Loacker L, Neuwirth H, Mayer G, Bechtold T. Separation of metabolic products by electroosmotic dialysis in the plasma model. Electrochim Acta 2017. [DOI: 10.1016/j.electacta.2017.11.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Thorpy M, Dauvilliers Y, Shapiro C, Mayer G, Corser B, Chen D, Li J, Carter L, Wang H, Black J, Emsellem H. A randomized, placebo-controlled, phase 3 study of the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with narcolepsy. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.961] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
|
33
|
Shirsath N, Wagner K, Ober J, Mayer G, Schlederer M, Roos S, Kenner L, Wolf P. 635 PUVA diminishes imiquimod-induced psoriatic phenotype with gene expression signature associated with senescence. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
|
35
|
Bisson G, Bret G, Denariez M, Gires F, Mayer G, Paillette M. L’émission Raman stimulée sans cavité résonnante extérieure. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1967640197] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
36
|
Thorpy MJ, Dauvilliers Y, Shapiro C, Mayer G, Corser BC, Chen D, Li J, Carter LP, Wang H, Lu Y, Black J, Emsellem H. 0675 A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF JZP-110 FOR THE TREATMENT OF EXCESSIVE SLEEPINESS IN PATIENTS WITH NARCOLEPSY. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.674] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Riemann D, Baum E, Cohrs S, Crönlein T, Hajak G, Hertenstein E, Klose P, Langhorst J, Mayer G, Nissen C, Pollmächer T, Rabstein S, Schlarb A, Sitter H, Weeß HG, Wetter T, Spiegelhalder K. S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 2017. [DOI: 10.1007/s11818-016-0097-x] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
38
|
Viricel W, Poirier S, Mbarek A, Derbali RM, Mayer G, Leblond J. Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery. Nanoscale 2017; 9:31-36. [PMID: 27906384 DOI: 10.1039/c6nr06701h] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A pH-sensitive molecular switch able to change its conformation upon protonation at endosomal pH values is embedded into the structure of cationic lipidoid materials, thus conferring endosomal escape properties. Involvement of the conformational switch in the endosomal escape process was confirmed and leading material identified was able to induce efficient gene knockdown both in vitro and in vivo. The lipid nanoparticles reported here are promising for therapeutic applications and this work could serve as a template for future design of stimulus-responsive (ionic, redox, light) molecular switch for drug and gene delivery.
Collapse
Affiliation(s)
- W Viricel
- Faculty of Pharmacy, University of Montreal, P.O. Box 6128, Downtown Station, Montreal, QC, Canada.
| | | | | | | | | | | |
Collapse
|
39
|
Lavoie J, Sock EN, Mayer G. Effects of rosuvastatin on gene expression of liver LDL-R, Pcsk9, SREBP-2, and Lrp1 in ovariectomized rats submitted or not to voluntary exercise. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Lhotta K, Würzner R, Rosenkranz AR, Beer R, Rudisch A, Neumair F, Mayer G. Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus 2016; 13:139-41. [PMID: 14995009 DOI: 10.1191/0961203304lu489cr] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We describe the case of a female patient with hereditary complete C4 deficiency and systemic lupus erythematosus. She had suffered from lupus nephritis in early childhood. At the age of 23 years she developed severe lupus with skin disease and life-threateningcerebral vasculitis. Her cerebral disease was unresponsiveto high-dosesteroids, intravenousimmunoglobulin, fresh frozen plasma and plasma exchange. Improvement was achieved with immunoadsorption in combination with mycophenolate mofetil. The patient made a complete recovery and is maintained in complete remission on mycophenolate and low-dose steroids.
Collapse
Affiliation(s)
- K Lhotta
- Division of Clinical Nephrology, Department of Internal Medicine, Innsbruck University Hospital, Innsbruck, Austria.
| | | | | | | | | | | | | |
Collapse
|
41
|
Mayer G. [Sleep and neurological diseases]. Nervenarzt 2016; 87:616-622. [PMID: 27167889 DOI: 10.1007/s00115-016-0117-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Knowledge of the physiology of sleep-wake regulation can contribute to an understanding of the pathophysiology and symptoms of neurological diseases and is helpful for initiating specific therapies for sleep-wake cycle stabilization. Based on historically important observations on the close relationship between sleep and neurological diseases, new insights and developments in selected neurological entities are presented in this review article.
Collapse
Affiliation(s)
- G Mayer
- Hephata Klinik, Schimmelpfengstr. 6, 34613, Schwalmstadt, Deutschland.
| |
Collapse
|
42
|
Snow DE, Everett J, Mayer G, Cox SB, Miller B, Rumbaugh K, Wolcott RA, Wolcott RD. The presence of biofilm structures in atherosclerotic plaques of arteries from legs amputated as a complication of diabetic foot ulcers. J Wound Care 2016; 25:S16-22. [PMID: 26878370 DOI: 10.12968/jowc.2016.25.sup2.s16] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Atherosclerosis, rather than microcirculatory impairment caused by endothelial cell dysfunction, is the main driver of circulatory compromise in patients with diabetic limbs. The presence of atherosclerotic plaque at the trifurcation is a significant contributor to amputation of diabetic legs. The presence of bacteria and other microorganisms in atherosclerotic plaque has long been known, however, the cause of chronic inflammation and the role of bacteria/viruses in atherosclerosis have not been studied in detail. The objective of this study was to clarify the cause of the chronic inflammation within atherosclerotic plaques, and determine if any bacteria and/or viruses are involved in the inflammatory pathway. METHOD This study uses fluorescence microscopy and fluorescence in-situ hybridisation (FISH) to identify components of biofilm in atherosclerotic arteries. These tools are also used to identify individual bacteria, and determine the architectural spatial location within the atherosclerotic plaque where the bacteria can be found. RESULTS The results indicate that the presence of biofilms in grossly involved arteries may be an important factor in chronic inflammatory pathways of atherosclerotic progression, in the amputated limbs of patients with diabetic foot ulcers and vascular disease. CONCLUSION While the presence of bacterial biofilm structures in atherosclerotic plaque does not prove that biofilm is the proximate cause of atherosclerosis, it could contribute to the persistent inflammation associated with it. Second, the synergistic relationship between the atherosclerotic infection and the diabetic foot ulcer may ultimately contribute to higher amputation rates in diabetics. DECLARATION OF INTEREST RAW and RDW have equity interest in PathoGenius, a clinical laboratory using DNA to identify microbes.
Collapse
Affiliation(s)
- D E Snow
- The Institute of Environmental and Human Health, Texas Tech University, Lubbock Texas
| | - J Everett
- Department of Surgery, Texas Tech University Health Sciences Center School of Medicine, Lubbock Texas
| | - G Mayer
- The Institute of Environmental and Human Health, Texas Tech University, Lubbock Texas
| | - S B Cox
- Research and Testing Laboratory, Lubbock Texas
| | - B Miller
- Eli Lilly and Company, Indianapolis
| | - K Rumbaugh
- Department of Surgery, Texas Tech University Health Sciences Center School of Medicine, Lubbock Texas
| | - R A Wolcott
- Research and Testing Laboratory, Lubbock Texas
| | - R D Wolcott
- Research and Testing Laboratory, Lubbock Texas.,Southwest Regional Wound Care Center, Lubbock Texas
| |
Collapse
|
43
|
Domenyuk V, Zhong Z, Wang J, Stark A, Chen W, Xiao N, Miglarese MR, Famulok M, Mayer G, Spetzler DB. Abstract P2-01-08: Adaptive dynamic artificial poly-ligand targeting: Aptamer-based profiling of liquid biopsies to improve the accuracy of breast cancer diagnoses in women with dense breast tissue. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:
Breast cancer screening relies upon mammography, but for women with dense breast tissue this method is often uninformative. Routine screening identifies suspicious breast lesions in some women, but the pain and risk associated with follow-up biopsies along with the poor accuracy of traditional histopathology urgently call for improved approaches to breast cancer screening. This is especially important for those high-risk patients for whom mammography is of limited value. We describe a non-invasive liquid biopsy method of profiling plasma exosome preps designed to improve the accuracy and safety of breast cancer screening for women with dense breast tissue.
Results:
We incubated plasma samples (300 microliters per sample) from breast cancer patients (n=60) and a control cohort (n=60) with a high-complexity DNA aptamer library using a modified SELEX scheme, termed “adaptive dynamic artificial poly-ligand targeting (ADAPTTM)”. Differentially bound (cancer vs. non-cancer) aptamers were recovered from precipitated exosomes and were identified by deep sequencing. Two thousand aptamer sequences were resynthesized and used to probe a larger set of 500 plasma samples from a patient cohort (n=206) and a control cohort comprised of self-reported healthy volunteers (n=117) and patients whose biopsies led to a diagnosis of non-cancer (n=177). We employed several statistical models to build a cancer/non-cancer predictor, including a Random Generalized Linear Model (RGLM) and a Random Forest Model (RFM). Both models yielded an equivalent classification performance with areas under the receiver-operator characteristic curve (ROC AUC) of 0.7. Testing the prediction performance by 100 Out-of-Bag permutations or by pre-filtered (read cutoff and estimated sample size) cross-validation (CV) resulted in ROC AUC values of 0.66 and 0.62, respectively. When samples were randomly assigned to groups, the aptamers were no longer able to distinguish the groups (ROC AUC = 0.54), indicating that the underlying information driving the model is truly specific to cancer. Importantly, incorporation of BIRAD results as a clinical covariate did not influence model performance, signifying that predictions by ADAPTTM were independent of breast tissue density.
Conclusions:
We have identified a set of 2000 DNA aptamers that distinguish women with breast cancer from women without breast cancer. Our liquid biopsy approach requires only 300 microliters of plasma and is amenable to high-throughput processing. By employing a number of statistical approaches including rigorous cross-validation, we consistently achieve cross validation ROC AUC values approaching 0.7. The performance of the predictor was not affected by BIRAD scores, supporting its potential utility in difficult cases where imaging is insufficient, such as in women with dense breast tissue. Further optimization of the aptamer library and testing on additional samples should improve performance. Upon complete validation, an ADAPTTM – derived breast cancer test may serve as a vital diagnostic adjunct that can be easily incorporated into standard clinical practice.
Citation Format: Domenyuk V, Zhong Z, Wang J, Stark A, Chen W, Xiao N, Miglarese MR, Famulok M, Mayer G, Spetzler DB. Adaptive dynamic artificial poly-ligand targeting: Aptamer-based profiling of liquid biopsies to improve the accuracy of breast cancer diagnoses in women with dense breast tissue. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-01-08.
Collapse
Affiliation(s)
- V Domenyuk
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - Z Zhong
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - J Wang
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - A Stark
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - W Chen
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - N Xiao
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - MR Miglarese
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - M Famulok
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - G Mayer
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| | - DB Spetzler
- Caris Life Sciences, Phoenix, AZ; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research, Bonn, Germany; LIMES Program Unit Chemical Biology & Medicinal Chemistry, Kekulé Institut für Organische Chemie und Biochemie, University of Bonn, Bonn, Germany
| |
Collapse
|
44
|
Dahms C, Guenther A, Schwab M, Schultze T, Nowack S, Hoyer D, Ehrhardt J, Witte OW, Mayer G, Rupprecht S. Dysautonomia in prodromal α-synucleinopathy: peripheral versus central autonomic degeneration. Eur J Neurol 2016; 23:878-90. [PMID: 26842960 DOI: 10.1111/ene.12957] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 12/04/2015] [Indexed: 12/24/2022]
Abstract
BACKGROUND AND PURPOSE There is an urgent need for early predictive markers for the course of disease in prodromal α-synucleinopathies such as idiopathic rapid eye movement (REM) sleep behaviour disorder. Autonomic cardiac/vascular dysfunction is a prominent feature in advanced α-synucleinopathies, but its diagnostic value as an early neurodegenerative marker remains unclear. The latter may be complicated since synuclein-mediated neurodegeneration may involve central and peripheral components of the autonomic nervous system. METHODS The diagnostic value of autonomic symptoms and central and peripheral autonomic markers of blood pressure and heart rate regulation were prospectively evaluated in 20 subjects with idiopathic REM sleep behaviour disorder and 20 age-matched healthy controls. RESULTS Although subjects with REM sleep behaviour disorder showed no clinical autonomic symptoms, blood pressure (P ≤ 0.035) and heart rate response (P ≤ 0.065) were slightly diminished during orthostatic challenge. Autonomic dysregulation was distinctively reflected in lower resting heart rate (all components, P ≤ 0.05) and blood pressure variability (low frequency component, P ≤ 0.024) indicating peripheral cardiac/vascular denervation. In contrast, baroreflex sensitivity and central cardiac autonomic outflow (sympathovagal balance) were well preserved indicating intact central autonomic regulation. Heart rate variability [very low frequency component, receiver operating characteristic (ROC) area under the curve (AUC) 0.80, P ≤ 0.001] and blood pressure variability (low frequency component ROC AUC 0.73, P ≤ 0.01) but not baroreflex sensitivity and sympathovagal balance showed an excellent diagnostic accuracy in identifying subjects with REM sleep behaviour disorder and healthy controls. CONCLUSIONS Cardiac/vascular dysfunction in prodromal α-synucleinopathy arises from peripheral rather than from central autonomic degeneration. Autonomic indices encoded in heart rate and blood pressure variability are precise functional markers of early synuclein-mediated neurodegeneration.
Collapse
Affiliation(s)
- C Dahms
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - A Guenther
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - M Schwab
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - T Schultze
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - S Nowack
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - D Hoyer
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - J Ehrhardt
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - O W Witte
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - G Mayer
- Hephata Hospital, Schwalmstadt-Treysa, Germany
| | - S Rupprecht
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| |
Collapse
|
45
|
Mayer G, Drechsel-Bäuerle U, Schmidtmann I, Keller-Stanislawski B, Oberle D. Incidence of narcolepsy in Germany. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Poirier S, Mamarbachi M, Lee A, Mayer G. GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Chen XN, Andriolo L, Rineiski A, Bubelis E, Mayer G, Bentivoglio F. Extension and validation of SIMMER III code for gas cooled fast reactor. ANN NUCL ENERGY 2015. [DOI: 10.1016/j.anucene.2015.03.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
48
|
Mayer G, Rodenbeck A, Geisler P, Schulz H. Internationale Klassifikation der Schlafstörungen: Übersicht über die Änderungen in der ICSD-3. Somnologie 2015. [DOI: 10.1007/s11818-015-0006-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Reingewertz TH, Iosub-Amir A, Bonsor DA, Mayer G, Amartely H, Friedler A, Sundberg EJ. An Intrinsically Disordered Region in the Proapoptotic ASPP2 Protein Binds to the Helicobacter pylori Oncoprotein CagA. Biochemistry 2015; 54:3337-47. [PMID: 25963096 DOI: 10.1021/acs.biochem.5b00084] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The leading risk factor for gastric cancer in humans is infection by Helicobacter pylori strains that express and translocate the oncoprotein CagA into host epithelial cells. Once inside host cells, CagA interacts with ASPP2, which specifically stimulates p53-mediated apoptosis and reverses its pro-apoptotic function to promote ASPP2-dependent degradation of p53. The X-ray crystal structure of a complex between the N-terminal domain of CagA and a 56-residue fragment of ASPP2, of which 22 residues were resolved, was recently described. Here, we present biochemical and biophysical analyses of the interaction between the additional regions of CagA and ASPP2 potentially involved in this interaction. Using size exclusion chromatography-multiangle laser light scattering, circular dichroism, and nuclear magnetic resonance analyses, we observed that the ASPP2 region spanning residues 331-692, which was not part of the ASPP2 fragment used for crystallization, is intrinsically disordered in its unbound state. By surface plasmon resonance analysis and isothermal titration calorimetry, we found that a portion of this disordered region in ASPP2, residues 448-692, binds to the N-terminal domain of CagA. We also measured the affinity of the complex between the ASPP2 fragment composed of residues 693-918 and inclusive of the fragment used for crystallization and CagA. Additionally, we mapped the binding regions between ASPP2 and CagA using peptide arrays, demonstrating interactions between CagA and numerous peptides distributed throughout the ASPP2 protein sequence. Our results identify previously uncharacterized regions distributed throughout the protein sequence of ASPP2 as determinants of CagA binding, providing mechanistic insight into apoptosis reprogramming by CagA and potential new drug targets for H. pylori-mediated gastric cancer.
Collapse
Affiliation(s)
| | - Anat Iosub-Amir
- ‡Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | | | - Guy Mayer
- ‡Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | - Hadar Amartely
- ‡Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | - Assaf Friedler
- ‡Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | | |
Collapse
|
50
|
Abstract
Narcolepsy is a rare sleep disorder. The classical presentation includes the four symptoms excessive daytime sleepiness, cataplexy, sleep paralysis and hypnagogic hallucinations. As a model disease with all the transitions from awake to sleeping conditions, non-rapid eye movement (NREM) and rapid eye movement (REM), it plays an important role in neurology and sleep medicine. Patients with narcolepsy possess a reduced number of hypocretin-producing neurons in the hypothalamus and accordingly the hypocretin level in the cerebrospinal fluid is low. The neuropeptide hypocretin (orexin) has functions, such as the regulation of the sleep-wake cycle, the autonomous nerve system, motor system and metabolic processes. The delay in diagnosing narcolepsy is difficult to comprehend in modern medicine. The frequent association with other sleep-wake disorders may be responsible for the delay. Genomewide association studies have subsequently been able to prove that autoimmune mechanisms are responsible for the manifestation of narcolepsy with the HLA association being the most important for susceptibility and protection. Imaging studies have revealed neurodegenerative changes, making a multifactorial etiopathogenesis probable. The frequent occurrence of metabolic disorders has not yet been clarified. Early diagnosis of narcolepsy has the possibility to offer affected persons an adequate medication to lead an almost normal life and the future possibility to cure narcolepsy through immunomodulation therapy.
Collapse
Affiliation(s)
- G Mayer
- Klinik für Neurologie, Hephata Klinik, Philipps-Universität Marburg, Schimmelpfengstr. 6, 34613, Schwalmstadt-Treysa, Deutschland,
| |
Collapse
|